Foreite Pharma

Foreite Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics for autoimmune diseases and oncology. The company focuses on highly selective kinase inhibitors, particularly targeting the Janus kinase (JAK) family to provide safer and more effective treatments for chronic inflammatory conditions. Its lead candidate, FR-001, is a potent and selective TYK2/JAK1 inhibitor currently undergoing clinical evaluation for dermatological and systemic autoimmune indications. Foreite Pharma leverages its internal R&D capabilities to advance a pipeline of next-generation inhibitors designed to minimize off-target toxicities associated with first-generation pan-JAK inhibitors.